DSG-Panel-Erbkrankheiten

TEST AND PRICE LIST FOR NEXT GENERATION SEQUENCING

AIP ALK APC Mutation Detection Techniques Ai Saple Type TAT ATM BAP1 BLM BMPR1A BRCA1 BRCA2 BRIP1 BUB1B CDC73 CDH1 CDK4 CDKN1C CDKN2A CEBPA CEP57 CHEK2 CYLD DDB2 DICER1 DIS3L2 EGFR EPCAM ERCC2 ERCC3 ERCC4

Next-generation sequencing can replace Sanger sequencing in clinical diagnostics.

Next-generation sequencing can replace Sanger sequencing in clinical diagnostics. Birgit Sikkema-Raddatz Department of Genetics, University Medical Center Groningen The Netherlands Groningen GRONINGEN

CLINICAL TEST PRICES BY DISEASE

Targeted Testing of Familial Mutations 100 Single exon sequencing of gene $190 200 Double exon sequencing of gene $340 300 Triple exon sequencing of gene $390 Deletion/Duplication 600 acgh $990-1,490 3-M

Genetics and Cardiovascular diseases. Majid Alfadhel Geneticist and Pediatrician MD,MHSc,SSC Ped, ABHS(CH), FCCMG

Genetics and Cardiovascular diseases Majid Alfadhel Geneticist and Pediatrician MD,MHSc,SSC Ped, ABHS(CH), FCCMG Outlines Basic understanding of cardiovascular genetics Modes of disease inheritance Genetic

9/17/2014. Conflict of Interest Disclosure. Support Foundation Fighting Blindness National Institutes of Health

Eye Can See Clearer Now: Genetic Counseling and Genetic Testing for Retinitis Pigmentosa Kari Branham, MS, CGC University of Michigan Kellogg Eye Center Conflict of Interest Disclosure In relation to this

Approaches to Integrating Next Generation Sequencing into the Electronic Health Record

AMIA Webinar April 16, 2014 Approaches to Integrating Next Generation Sequencing into the Electronic Health Record Peter Tarczy-Hornoch, University of Washington On behalf of the Clinical Sequencing Exploratory

1199 SEIU Benefit Funds Laboratory Management Program PRIOR AUTHORIZATION CODE LIST FOR OUTPATIENT MOLECULAR AND GENOMIC LABORATORY TESTS

1199 SEIU Benefit Funds Laboratory Management Program PRIOR AUTHORIZATION CODE LIST FOR OUTPATIENT MOLECULAR AND GENOMIC LABORATORY TESTS Effective January 1, 2016 Administered by evicore healthcare Refer

2014 CPT Code Updates

2014 CPT Code Updates This publication is a summary of The American Medical Association Current Procedural Terminology (CPT) codes published in ARUP's Laboratory Test Directory effective January 1, 2014.

MEDICAL POLICY Genetic Testing

POLICY.........PG0041 EFFECTIVE......01/01/12 LAST REVIEW... 04/22/16 MEDICAL POLICY Genetic Testing GUIDELINES This policy does not certify benefits or authorization of benefits, which is designated by

Identification of Genetic Alterations, as Causative Genetic Defects in Long QT Syndrome, Using Next Generation Sequencing Technology

RESEARCH ARTICLE Identification of Genetic Alterations, as Causative Genetic Defects in Long QT Syndrome, Using Next Generation Sequencing Technology Oscar Campuzano 1., Georgia Sarquella-Brugada 2., Irene

Laboratory User Guides

CLINICAL GENETIC SERVICE Laboratory User Guides (Website version) January 2016 DEPARTMENT OF HEALTH GOVERNMENT OF HONG KONG SAR Page 1 of 10 Compared with the previous version of January 2015, several

LISTE DES ANALYSES HORS-QUEBEC List for testing done out of Québec LABORATOIRE CLINIQUES CUSM MUHC CLINICAL LABS

APPELATION APPROUVÉE DE OU DE LA MALADIE 11-ß-prostaglandin F2α 21-Hydroxylase Antibodies, Serum [OH21] 68kD (hsp-70) [F68KD] a1-acid glycoprotein autoimmume adrenal failure autoimmune hearing loss Obsolete

Doenças Raras de Demais Especialidades

Informações do Paciente (Patient Information) Teste solicitado (test requested) Nome ( First Name) Sobrenome (Last Name) Escreva o nome do gene/doença abaixo ou selecione nas páginas 2-7: (Write gene /

Tabella 1: PrenatalScreen - Elenco dei geni analizzati e della malattie genetiche investigate

Tabella 1: PrenatalScreen - Elenco dei geni analizzati e della malattie genetiche investigate MALATTIA PhenoMIM GENE 1 17-alpha-hydroxylase/17,20-lyase deficiency 202110 CYP17A1 2 17-beta-hydroxysteroid

LISTE DES ANALYSES HORS-QUEBEC List for testing done out of Québec LABORATOIRE CLINIQUES CUSM MUHC CLINICAL LABS

11 Beta-Prostaglandin F2 Alpha, 24 Hour, Urine [BPG2] Systemic mast cell disease Urine. Add to container 25 ml 50% HAc. Collect for 24-h. Refrigeate 4 C during collection. Store frozen. Enzyme Immunoassay

CIC Edizioni Internazionali

Introducing the next generation sequencing in genomic amnio and villuos sampling. The so called Next Generation Prenatal Diagnosis (NGPD) Claudio Giorlandino 1 Alvaro Mesoraca 2 Domenico Bizzoco 2 Claudio

Canadian Journal of Cardiology 27 (2011) 232 245. Society Position Statement

Canadian Journal of Cardiology 27 (2011) 232 245 Society Position Statement Recommendations for the Use of Genetic Testing in the Clinical Evaluation of Inherited Cardiac Arrhythmias Associated with Sudden

Molecular Human Genetics. Cancer, Tumor suppressor genes, Oncogenes

Youtube ARCC http://www.youtube.com/watch?v=3pobqrfz0no It's Our Time - American Association for Cancer Research (AACR) Molecular Human Genetics Cancer, Tumor suppressor genes, Oncogenes Hum 2014/15 1

PATH-SCAN: A REPORTING TOOL FOR IDENTIFYING CLINICALLY ACTIONABLE VARIANTS

PATH-SCAN: A REPORTING TOOL FOR IDENTIFYING CLINICALLY ACTIONABLE VARIANTS ROXANA DANESHJOU 1, ZACHARY ZAPPALA 1, KIM KUKURBA 1, SEAN M BOYLE 1, KELLY E ORMOND 1, TERI E KLEIN 1, MICHAEL SNYDER 1, CARLOS

Guidelines for Genetic Testing of Inherited Cardiac Disorders

The Cardiac Society of Australia and New Zealand Guidelines for Genetic Testing of Inherited Cardiac Disorders Development of this guideline by Ms Poonam Zodgekar, Ms Jodie Ingles, Ms Laura Yeates, Mr

Xenética e Xenómica: o seu impacto en Medicina

Xenética e Xenómica: o seu impacto en Medicina Angel Carracedo Fundación Pública Galega de Medicina Xenómica- Consellería de Sanidade Grupo de Medicina Xenómica- IML-Universidad de Santiago de Compostela

JOHNS HOPKINS HEALTHCARE

Page 1 of 15 ACTION: New Policy: Effective Date: 08/26/2003 Revising : Review Dates: 03/15/2004, 10/22/2004, Superseding : 10/21/2005, 10/19/2006, 01/07/2008, Archiving : 01/05/2009, 01/07/2011, 06/07/2013,

Rare Mendelian Disorders Test Requisition Form

Rare Mendelian Disorders Test Requisition Form For oncology, neurology/mitochondrial disorders, cardiology, array CGH, FISH, whole exome sequencing or prenatal testing please use specific submission forms

Cardio Gene panel experience. Jan Jongbloed Laboratory Specialist Clinical Genetics Genome Diagnostics Department of Genetics UMCG Groningen

Cardio Gene panel experience Jan Jongbloed Laboratory Specialist Clinical Genetics Genome Diagnostics UMCG Groningen CardioGenetics: Rowida Almomani Ludolf Boven Anne Herkert Yvonne Hoedemaekers Irene

LISTE DES ANALYSES HORS-QUEBEC List for testing done out of Québec LABORATOIRE CLINIQUES CUSM MUHC CLINICAL LABS

APPELATION APPROUVÉE DE OU DE LA MALADIE ASSOCIÉE 11-ß-prostaglandin F2a urine, collect 4 C, 25 ml 50% Hac 21-Hydroxylase Antibodies, Serum autoimmume adrenal Red Top; store serum failure frozen a1-acid

MEDICAL POLICY No. 91540-R10 GENETICS: COUNSELING, TESTING, SCREENING

GENETICS: COUNSELING, TESTING, SCREENING Effective Date: February 26, 2015 Review Dates: 8/07, 10/07, 8/08, 8/09, 10/09, 2/10, 8/10, 8/11, 10/11, 10/12, 10/13, 11/14 Date Of Origin: August 8, 2007 Status:

The Genetics of Hearing Loss. Heidi L. Rehm, Ph.D. Harvard Medical School Boston, MA

The Genetics of Hearing Loss Heidi L. Rehm, Ph.D. Harvard Medical School Boston, MA Faculty Disclosure Information In the past 12 months, I have not had a significant financial interest or other relationship

HEART GENE PANEL DG 2.3.x

HEART GENE PANEL DG 2.3.x Gene Median % covered > % covered > Associated Phenotype description and OMIM ID coverage 10x 20x AARS2 94,1 99% 98% Combined oxidative phosphorylation deficiency 8, 614096 ABCC6

ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing

American College of Medical Genetics and Genomics ACMG Policy Statement ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing Robert C. Green, MD, MPH 1,2, Jonathan

GeneScreen : Elenco dei geni analizzati e malattie genetiche investigate

GeneScreen : Elenco dei geni analizzati e malattie genetiche investigate DISEASE NAME PhenoMIM GENE 1 17-alpha-hydroxylase/17,20-lyase deficiency 202110 CYP17A1 2 17-beta-hydroxysteroid dehydrogenase X

RMHP Prior Authorization List Effective October 1, 2015 rev 7/18/2016

Effective October 1, 2015 rev 7/18/2016 *This list applies to all services for which RMHP is the primary payer. * Services that are not a benefit of the Member's Evidence of Coverage will not be authorized.

Genetic Tests and Disease States Included in Humana s Genetic Guidance Program

81161 81200 81201 Dystrophin (DMD) (e.g., Duchenne/Becker muscular dystrophy) deletion analysis and duplication analysis, if performed Aspartoacylase (ASPA) (e.g., Canavan disease) gene analysis, common

Single Gene and NextGen Panels

Molecular Testing for Hearing Loss: Single Gene and NextGen Panels Honey V Reddi, PhD, FACMG Clinical Molecular Geneticist Prevention Genetics, Marshfield, WI www.preventiongenetics.com Outline of Presentation

Selection of non-synonymous variants in RP genes yielded an average of 84

Results S1: screening for mutations in known RP genes Selection of non-synonymous variants in RP genes yielded an average of 84 variants (vars) per genome (Figure S1). For the sake of clarity, we define

Non-urgent Pre-service requests---within 3 business days of receipt of request. Urgent Pre-service requests---within 72 hours of receipt of request

Health Republic Insurance of New York Services Requiring Preauthorization Effective January 1, 2015 Applies to all Lines of Business unless specifically noted Non-Participating Provider services are not

Section: Genetic Testing Last Reviewed Date: October 2015. Policy No: 73 Effective Date: November 1, 2015

Medical Policy Manual Topic: Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Date of Origin: July 2014 Section: Genetic Testing Last Reviewed Date: October 2015 Policy No: 73 Effective

EPILEPSY. www.amplexa.com. Childhood Epilepsy Epilepsy Associated Brain Malformation (EA-BMF40) Progressive Myoclonic Epilepsy

EPILEPSY Childhood Epilepsy Epilepsy Associated Brain Malformation (EA-BMF40) Progressive Myoclonic Epilepsy 1 in 10 cases of epilepsy is believed to be hereditary. A clear diagnosis is the first step.

dagan.wells@obs gyn.ox.ac.ukgyn.ox.ac.uk

In vitro fertilisation and genetic testing Dagan Wells, PhD, FRCPath dagan.wells@obs gyn.ox.ac.ukgyn.ox.ac.uk Infertility Unprotected intercourse for 1 year without conception Very common 1 in 6 couples

Health First Health Plans Authorization List

Health First Health Plans Authorization List Effective April 15, 2016 IMPORTANT CONTACTS FOR AUTHORIZATIONS SUBMITTED TO THE HEALTH PLAN Submit online requests via your secure account at MyHFHP.org/login

Corporate Medical Policy

Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_epilepsy 1/28/14 10/2015 10/2016 10/2015 Description of Procedure or Service Description

Molecular Pathology/Molecular Diagnostics/Genetic Testing

Policy Number GEN01252012RP Approved By UnitedHealthcare Medicare Reimbursement Policy Committee Current Approval Date 01/28/2015 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is applicable

July 14, 2014. Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244

ASCP s Statements before the Centers for Medicare and Medicaid Services Regarding Recommendations for Crosswalking/Gapfilling New CPT s for the CLFS for CY 2015 and the Revaluation of the Clinical Laboratory

Verzeichnis der seltenen Krankheiten und Synonyme

Marche des Maladies Rares Alliance Maladies Rares Dezember December 2014 2009 Verzeichnis der seltenen Krankheiten und Synonyme Auflistung in alphabetischer Reihenfolge www.orpha.net Seltene Krankheiten

NEW YORK STATE MEDICAID PROGRAM LABORATORY PROCEDURE CODES

NEW YORK STATE MEDICAID PROGRAM LABORATORY PROCEDURE S Table of Contents GENERAL INFORMATION AND RULES...3 ORGAN OR DISEASE ORIENTED PANELS... 14 THERAPEUTIC DRUG ASSAYS... 15 EVOCATIVE/SUPPRESSION TESTING...

G. Shashidhar Pai, MD MUSC Children s Hospital Department of Pediatrics Division of Genetics

G. Shashidhar Pai, MD MUSC Children s Hospital Department of Pediatrics Division of Genetics One of every 500 newborns has bilateral permanent sensorineural hearing loss 40 db which makes it the most common

Genetic Testing for Hereditary Hearing Loss

MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Genetic Testing for Hereditary Hearing Loss Number 12.04.87 Effective

Test Information Sheet

Test Information Sheet GeneDx 207 Perry Parkway Gaithersburg, MD 20877 Phone: 888-729-1206 Fax: 301-710-6594 E-mail: wecare@genedx.com www.genedx.com/oncology OncoGene Dx: High/Moderate Risk Panel Sequence

The importance of Big Data to the L&H insurance industry

w w w. I C A 2 0 1 4. o r g The importance of Big Data to the L&H insurance industry Daniel Ryan, Swiss Re 1 Our Brave New World 2 Who knows what about me? Married for 17 years Age: 42 Father of 2 SN8

Global topological features of cancer proteins in the human interactome

Global topological features of cancer proteins in the human interactome Pall F. Jonsson and Paul A. Bates Protein communities identified by k-clique clustering. KEGG pathway data is provided for proteins

HEREDITARY CANCER GENE PANEL DG 2.3.x

HEREDITARY CANCER GENE PANEL DG 2.3.x Gene Median % covered % covered Associated Phenotype description and OMIM ID coverage >10x >20x ALK 99,5 100% 98% {Neuroblastoma, susceptibility to, 3}, 613014 APC

Oncomine Cancer Panel Patient Test Report

Oncomine Cancer Panel Patient Test Report SUBJECT NFORMATON Pre-Screening Subject No.: Life Technologies Clinical Services Lab 910 Riverside Parkway, Suite 60 West Sacramento, CA 95605 Ph: (888) 734-8588

Maternal hyperglycemia and foetal epigenetic adaptations

Note: for non-commercial purposes only Maternal hyperglycemia and foetal epigenetic adaptations Marie-France Hivert, MD, MMSc Harvard Pilgrim Health Care Institute, Department of Population Medicine Harvard

Comprehensive List of Neuromuscular Disorders Covered by Muscular Dystrophy Canada

Comprehensive List of Neuromuscular Disorders Covered by Muscular Dystrophy Canada Neuromuscular disorders is a general term that refers to diseases that affect any part of the nerve and muscle. These

GENETIC TESTING AND MARFAN SYNDROME

GENETIC TESTING AND MARFAN SYNDROME Genetic testing for mutations in fibrillin-1 (FBN1) and other genes has become an important and reliable option to aid in the diagnosis of Marfan syndrome and related

MULTIPLE CONGENITAL ANOMALIES GENE PANEL

MULTIPLE CONGENITAL ANOMALIES GENE PANEL Gene Depth Coverage OMIM symbol (reads) (avg %) disease Description A4GALT 105 100 111400 NOR polyagglutination syndrome AAAS 104 89 231550 Achalasia-addisonianism-alacrimia

The Genomics of Hearing Loss

The Genomics of Hearing Loss Ian Krantz, M.D. The Children s Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania Objectives 1. Understand the clinical and genetic

***Next Generation sequencing testing options available effective April 18 th, 2016***

***Next Generation sequencing testing options available effective April 18 th, 2016*** Genetic Test Next Generation Sequencing NF1-RASopathy Panel Testing NF1-only NGS testing and copy number analysis

ONE Paneli - 4813 gene) A2m BPGM CSF1R FFAR4 HOXB6 LPAR6 NPC1L1 PTGDS SLC5A2 TRIM5 A4GALT BPI CSF2 FGA HOXD10 LPIN1 NPC2 PTGER2 SLC5A5 TRIO A4GNT

ONE Paneli - 4813 gene) A2m BPGM CSF1R FFAR4 HOXB6 LPAR6 NPC1L1 PTGDS SLC5A2 TRIM5 A4GALT BPI CSF2 FGA HOXD10 LPIN1 NPC2 PTGER2 SLC5A5 TRIO A4GNT BPIFA1 CSF2RA FGB HOXD13 LPIN2 NPFFR2 PTGER4 SLC5A7 TRIOBP

***Next Generation sequencing testing options available effective April 18 th, 2016***

***Next Generation sequencing testing options available effective April 18 th, 2016*** Genetic Test Next Generation Sequencing NF1-RASopathy Panel Testing NF1-only NGS testing and copy number analysis

MENDELIOME GENE PANEL DG 2.4.x

MENDELIOME GENE PANEL DG 2.4.x Gene Median % covered % covered Associated phenotype description and OMIM disease ID coverage > 10x > 20x A4GALT 114.4 100% 100% NOR polyagglutination syndrome,111400 AAAS

A Decision Support Tool to Facilitate Cancer Risk Assessment and Referral for Genetics Services. Kristen Vogel Postula, MS, CGC & Leigh Baumgart, PhD

A Decision Support Tool to Facilitate Cancer Risk Assessment and Referral for Genetics Services Kristen Vogel Postula, MS, CGC & Leigh Baumgart, PhD Importance of Family History Increasing awareness of

rs1057909 CYP2C9 42612A>G G AA -/- rs4917639 CYP2C9 A6326C C AA -/-

Liver Detox - Phase I (Figure 1) rs1048943 CYP1A1*2C A4889G C CT +/- rs1799814 CYP1A1*4 C2453A T GG -/- rs2472304 CYP1A2*1F A AG +/- rs762551 CYP1A2*1F C164A C AA -/- rs2069526 CYP1A2*1K -739T>G G TT -/-

MENDELIOME GENE PANEL DGD141114

MENDELIOME GENE PANEL DGD141114 Gene Median % covered % covered Associated Phenotype description and OMIM ID coverage > 10x > 20x A4GALT 116.3 100% 100% [Blood group, P1Pk system, p phenotype], 111400

DUKE EP SYMPOSIUM. Long QT Syndrome: Genotype- Phenotype Correlations

DUKE EP SYMPOSIUM Long QT Syndrome: Genotype- Phenotype Correlations Arthur J. Moss, MD Professor of Medicine/Cardiology University of Rochester Med Center Rochester, NY Cary, NC January 21, 2011 CONFLICT

MULTIPLE CONGENITAL ANOMALIES GENE PANEL DGD20062014

MULTIPLE CONGENITAL ANOMALIES GENE PANEL DGD20062014 Gene Median coverage % covered > 10x % covered > 20x A4GALT 121,2 100% 100% Associated Phenotype description and OMIM ID [Blood group, P1Pk system,

Highlights from the MedSeq Project: ClinGen Meeting

Highlights from the MedSeq Project: ClinGen Meeting May 27, 2015 Robert C. Green, MD, MPH director, genomes2people Research Program in Translational Genomics and Health Outcomes Division of Genetics, Department

Genetic Testing for Hereditary Hearing Loss. Populations Interventions Comparators Outcomes Interventions of interest are: Genetic testing

Protocol Genetic Testing for Hereditary Hearing Loss (20487) Medical Benefit Effective Date: 01/01/15 Next Review Date: 11/16 Preauthorization Yes Review Dates: 01/14, 11/14, 11/15 Preauthorization is

ONKOLOJİ ALANINDA KULLANILAN DNA TESTLERİ

ONKOLOJİ ALANINDA KULLANILAN DNA TESTLERİ ADENOCARCINOMA OF LUNG, SOMATIC AFIBRINOGENEMIA» DYSFIBRINOGENEMIA FGA (FIBRINOGEN ALPHA) FGB (FIBRINOGEN BETA) FGG (FIBRINOGEN GAMMA) AGAMMAGLOBULINEMIA, NON-BRUTON

Copyright 2012 The Authors. http://eprints.gla.ac.uk/75131. Deposited on: 13 February 2013

Lee, C.M., Mudaliar, M.A.V., Haggart, D.R., Wolf, C.R., Miele, G., Vass, J.K., Higham, D.J., and Crowther, D. (2012) Simultaneous non-negative matrix factorization for multiple large scale gene expression

Long QT. Long QT Syndrome. A Guide for

Long QT Long QT Syndrome A Guide for Introduction Long QT syndrome (LQTS) is a genetic heart disorder due to the malfunction of cardiac ion channels that results in 4,000 deaths annually in the United

CPT Generic Test Test Description

CPT Generic Test Test Description Code Name 1 81200 ASPA Gene Test for leukodystrophies (Canavan disease), an autosomal recessive disease (most common in Ashkenazi Jewish population) with life expectancy

La diagnostica molecolare nelle neoplasie colo-rettali. A do Scarpa. U iversita di Vero a

La diagnostica molecolare nelle neoplasie colo-rettali C-NET A do Scarpa e Dipartime to Pato ogia e U iversita di Vero a La stessa malattia puo avere diverse patogenesi cucchiaio moneta forchetta Gastrointestinal

Genetic Testing for Hearing Loss

Genetic Testing for Hearing Loss S H O B A N A K U B E N D R A N, M B B S, M S, C G C G E N E T I C C O U N S E L O R A S S T P R O F E S S O R D E P T O F P E D I A T R I C S K U S M - W Objectives Indications

The Compassionate Allowances Initiative (CAL)

The Compassionate Allowances Initiative (CAL) CAL s objective is to quickly identify conditions that invariably meet Social Security disability standards CAL initiative began with a public outreach hearing

Corporate Medical Policy Genetic Testing for Hereditary Hearing Loss

Corporate Medical Policy Genetic Testing for Hereditary Hearing Loss File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_hereditary_hearing_loss 10/2013 8/2015 8/2016

National Medical Policy

National Medical Policy Subject: Policy Number: Genetic Testing for Long QT Syndrome NMP490 Effective Date*: February 2005 Updated: August 2015 This National Medical Policy is subject to the terms in the

Nuovi Scenari in Oncologia. G. Zoppoli X-Files in Nutrizione Clinica e Artificiale, 08/06/2012

Nuovi Scenari in Oncologia G. Zoppoli X-Files in Nutrizione Clinica e Artificiale, 08/06/2012 WHAT is cancer? «Cancer is a genetic disease of the somatic cell» [B. Vogelstein] Ten years ago Now [Cell.

Clinical Policy Title: Genetic Testing for Long QT Syndrome (LQTS)

Clinical Policy Title: Genetic Testing for Long QT Syndrome (LQTS) Clinical Policy Number: (391) 04.01.02 Effective Date: Dec. 1, 2013 Initial Review Date: June 19, 2013 Most Recent Review Date: July 17,

Medical Policy Manual. Date of Origin: October 2014. Topic: Genetic Testing for Hereditary Hearing Loss. Last Reviewed Date: December 2015

Medical Policy Manual Topic: Genetic Testing for Hereditary Hearing Loss Section: Genetic Testing Policy No: 36 Date of Origin: October 2014 Last Reviewed Date: December 2015 Effective Date: February 1,

Prior Authorization Updates

Prior Authorization Updates Managed Health Services (MHS) requires prior authorization as a condition of payment for many services. This Notice contains information regarding such prior authorization requirements

Prevalenza delle mutazioni TMEM127 nel feocromocitoma sporadico

Prevalenza delle mutazioni TMEM127 nel feocromocitoma sporadico Giuseppe Opocher Veneto Institute of Oncology and Department of Medical and Surgical Sciences, University of Padova, Italy Sympathetic paraganglia

Genetic Counselor Review of Genetic Test Orders in a Reference Laboratory Reduces Unnecessary Testing

RESEARCH ARTICLE Genetic Counselor Review of Genetic Test Orders in a Reference Laboratory Reduces Unnecessary Testing Christine E. Miller,* Patti Krautscheid, Erin E. Baldwin, Tatiana Tvrdik, Amanda S.

Launching a Cancer Genetic Laboratory to Enhance Diagnosis and Treatment

Launching a Cancer Genetic Laboratory to Enhance Diagnosis and Treatment Arthur L. Beaudet, M.D. Department of Molecular and Human Genetics Baylor College of Medicine ORIGIN AND PRECEDENT Decades of experience

Genetics of sudden death

Review Article Indian J Med Res 132, November 2010, pp 579-583 Genetics of sudden death Nitish Naik & Rakesh Yadav Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India Received

Table S1. OMIM entries of cytoskeletal genes

Table S1. OMIM entries of cytoskeletal genes HUMAN NEURONAL DISORDERS 1. ACTB 7 (ACTIN, BETA; 102630) - Baraitser-Winter syndrome 2 243310 (including microcephaly, intellectual disability, seizures, and

8 9 +

CPT Code Changes for 2015 PATHOLOGY/LABORATORY

Changes for 2015 PATHOLOGY/LABORATORY Rick Oliver, CPCO, CPC, MT(ASCP) Compliance Director- Laboratory and Pathology McKesson Business Performance Services This commentary is a summary prepared by McKesson

Prevalence, clinical and molecular correlates of KCNJ5 mutations in primary aldosteronism. Online Supplement

Prevalence, clinical and molecular correlates of KCNJ5 mutations in primary aldosteronism Online Supplement Sheerazed Boulkroun 1,2* PhD, Felix Beuschlein 3* MD, Gian-Paolo Rossi 4* MD, José-Felipe Golib-Dzib

Clinical Policy Title: Genetic Testing for Long QT Syndrome (LQTS)

Clinical Policy Title: Genetic Testing for Long QT Syndrome (LQTS) Clinical Policy Number: 04.01.02 Effective Date: Dec. 1, 2013 Initial Review Date: June 19, 2013 Most Recent Review Date: July 15, 2015

Note: This App is under development and available for testing on request. Note: This App is under development and available for testing on request. Note: This App is under development and available for

EBiSC: The European Bank for induced pluripotent Stem Cells

EBiSC: The European Bank for induced pluripotent Stem Cells Sadallah Fatiha 30.10.2014 Japan Health Sciences Foundation Visit IMI JU Office, Brussels, Belgium EBiSC Establish a European repository for

Computer-based Personal Nutrition Guidance Martin Kohlmeier, MD, PhD

Computer-based Personal Nutrition Guidance Martin Kohlmeier, MD, PhD University of North Carolina at Chapel Hill Department of Nutrition and UNC Nutrition Research Institute mkohlmeier@unc.edu Barriers

Pre-implantation genetic diagnosis: current status and future prospects

Francesco Florentino m8 Pre-implantation genetic diagnosis: current status and future prospects Couples who are carriers of genetic disorders, including recessive or dominant single-gene defects, sex-linked

MRC-Holland MLPA. Related SALSA MLPA probemixes P417 BAP1: Contains probes for each exon of BAP1 gene on 3p21.

SALSA MLPA probemix P027-C1 Uveal melanoma Lot C1-0814 & C1-0213 & C1-0211: A large number of probes have been replaced by other probes in the same chromosomal regions as compared to previous lots, and

How To Write A Cancer Sequencing

Evalua&ng tumor exome sequencing in the oncology clinic: Lessons from the BASIC3 study GBM Cancer Risk? A Clinical Sequencing Exploratory Research (CSER) project Supported by NHGRI/NCI 1U01HG006485 ISMB2014

Genomic instability in cancers and cancer predispositions. Popova Tatiana Inserm U830 Institut Curie

Genomic instability in cancers and cancer predispositions Popova Tatiana Inserm U830 Institut Curie Time-scale in a tumor genome discovery Bovery HYP Cancer genome Knudson 2 hit HYP Tumor DNA has transforming

1. Introduction. Academic Editor: Michael Levin

Hindawi ublishing Corporation Stem Cells International Volume 2013, Article ID 784629, 25 pages http://dx.doi.org/10.1155/2013/784629 Research Article Microarray-Based Comparisons of Ion Channel Expression

Objectives Role of Medical Genetics in Hearing Loss Evaluation. 5 y.o. boy with severe SNHL

Objectives Role of Medical Genetics in Hearing Loss Evaluation Millan Patel, MD UBC Dept. of Medical Genetics October 22, 2010 Case presentation to illustrate importance of defining syndromic hearing loss

The future role of genetic screening to detect newborns at risk of childhood-onset hearing loss

International Journal of Audiology 2013; 52: 124 133 Discussion Article The future role of genetic screening to detect newborns at risk of childhood-onset hearing loss Luan Linden Phillips *, Maria Bitner-Glindzicz,

Sudden unexplained death in infancy and long QT syndrome. Jonathan Robert Skinner

Sudden unexplained death in infancy and long QT syndrome. Jonathan Robert Skinner Greenlane Paediatric and Congenital Cardiac Services, Starship Children s Hospital, Park Road, Grafton, Auckland New Zealand.